Grapiprant Tablet Excipient Blends for PK and Palatability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of grapiprant, a prostaglandin E2 subtype 4 (EP4) receptor antagonist, face challenges in achieving optimal pharmacokinetic properties such as peak plasma concentration, time to reach maximum concentration (Tmax), half-life, and area under the plasma concentration curve (Cmax, AUC), while also ensuring palatability for non-human animals to enhance compliance.
Innovation Solution
A pharmaceutical composition comprising grapiprant with specific excipients like lactose, sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, copovidone, and poloxamer, administered at varying dosages and frequencies, achieves a Cmax of 375 ng/mL to 10000 ng/mL at Tmax of 0.4 to 3.4 hours, suitable for treating pain or inflammation in non-human animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If grapiprant is formulated with specific excipients and dosing regimens, then pharmacokinetic parameters (Cmax, Tmax, half-life, AUC) are optimized, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying excipient types and concentrations, dosing frequencies, and formulation compositions to optimize pharmacokinetic parameters. Multiple embodiments test different combinations of excipients (lactose, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, copovidone, poloxamer) at different concentrations to achieve desired Cmax, Tmax, half-life, and AUC values.
Solution Approach 2:
The patent employs composite materials by combining grapiprant with multiple excipients in specific ratios to create pharmaceutical compositions with optimized pharmacokinetic properties. The formulations use composite structures where excipients work synergistically to control drug release, absorption, and bioavailability, achieving reliable pharmacokinetic parameters while managing formulation complexity.
2Reliability
If grapiprant formulations are optimized for pharmacokinetic properties, then treatment efficacy is improved, but palatability may be compromised
Solution Approach 1:
The patent applies local quality by selecting excipients with specific functional properties that address different aspects of the formulation independently. For example, flavoring agents are added in specific concentrations (1-30% w/w) to improve palatability without affecting the core pharmacokinetic optimization achieved by other excipients. This allows simultaneous optimization of both efficacy and palatability by assigning different functional roles to different components.
Solution Approach 2:
The patent employs multi-functionality by selecting excipients that serve multiple purposes. For instance, microcrystalline cellulose and lactose not only act as fillers but also contribute to tablet disintegration and drug release characteristics. Sodium starch glycolate serves as both a binder and a disintegrant. This multi-functionality reduces the total number of excipients needed while maintaining both pharmacokinetic optimization and palatability.
3Reliability
If grapiprant is administered at higher dosages and frequencies, then pain and inflammation relief is enhanced, but risk of adverse effects increases
Solution Approach 1:
The patent applies periodic action by establishing specific dosing regimens with defined frequencies (at least once daily, at least twice daily, or at least thrice daily) and treatment durations (6 days to 9 months). The dosing intervals are optimized to maintain therapeutic blood concentrations while allowing adequate elimination periods, thereby maximizing pain and inflammation relief while minimizing cumulative adverse effects through rhythmic administration patterns.
Data Source
AI summary
The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.